Summary by Futu AI
On January 18, 2024, Incannex Healthcare Inc., a pharmaceutical company specializing in medicinal cannabinoid and psychedelic medicine therapies, announced the completion of dosing and treatment protocols for all participants in its PsiGAD-1 clinical trial. The trial, which took place at Monash University in Melbourne, Australia, involved 72 patients and is part of a Phase 2 study to evaluate the company's psilocybin treatment program for generalized anxiety disorder (GAD). The study aims to determine the efficacy of a 7-week psilocybin-assisted psychotherapy program compared to an active placebo. With safety and tolerability assessed, the trial also looks at secondary objectives of efficacy and quality of life. The interim analysis suggested a high probability of significant benefit for the psilocybin treatment over the placebo. Incannex is preparing an FDA IND application following the anticipated Q1 2024 topline results. Additionally, a documentary covering the Monash Clinical Psychedelic Lab and the PsiGAD research program is set to be released by the SBS television network in late February 2024.